Epirubicin: clinical toxicity during the phase II program in endometrial and cervical cancer

Eur J Gynaecol Oncol. 1992;13(1):83-9.


We have evaluated the clinical toxicity of Epirubicin 80 mg/m2 i.v., every 3 weeks in 58 patients with FIGO III-IV endometrial adenocarcinoma or squamous uterine cervix carcinoma. The median age of the whole group was 59 years (37-77); 37 patients were previously treated with radiotherapy and two with cisplatin based chemotherapy. The median KI at entry was 80. A total of 308 courses of chemotherapy were administered with a median of 5 per patient. Overall toxicity data shows that this dose level is associated with mild haematological toxicity with only two cases having grade 3 (WHO) leukopenia. Nine patients suffered emesis in spite of prophylactic therapy and were classified as grade 3. One case presented grade four diarrhoea but the relation with the antineoplastic treatment was uncertain. One woman with hepatic dysfunction at entry had grade 3 leukopenia, developed pneumonia and died. The median total cumulative dose of EPI was 360 mg/m2 (160-880) with 19 cases exposed to cumulative doses higher than 550 mg/m2. Congestive heart failure was not observed. Our data confirm the safety of EPI at these dose levels and suggest the possibility of developing new trials with higher doses of this anthracycline analog.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Alopecia / chemically induced
  • Drug Evaluation
  • Endometrial Neoplasms / drug therapy*
  • Epirubicin / adverse effects*
  • Epirubicin / therapeutic use
  • Female
  • Heart / drug effects
  • Humans
  • Leukopenia / chemically induced
  • Middle Aged
  • Spain
  • Uterine Cervical Neoplasms / drug therapy*
  • Vomiting / chemically induced


  • Epirubicin